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STENT OR SURGERY FOR MALIGNANT LOW
BILEDUCT OBSTRUCTION?
ABSTRACT
Smith, A. C., Dowsett, J.F., Russell, R. C. G., Hatfield, A.R. W. and Cotton, P.B. (1994)
Randomised trial of endoscopic stenting versus surgical bypass in malignant low
bileduct obstruction. The Lancet; 344." 1655-1660.
The development of non-surgical techniques for the relief of malignant low bileduct
obstruction has cast doubt on the best way of relieving jaundice, particularly in patients
fit for surgery whose life expectancy is more than a few weeks.
We did a randomised prospective controlled trial comparing endoscopic stent inser-
tion and surgical biliary bypass in patients with malignant low bileduct obstruction.
204 patients were randomised (surgery 103, stent 101); 3 subsequently proved to have
benign disease and were excluded, leaving 101 surgical and 100 stented patients for
assessment. Technical success was achieved in 94 surgical and 95 stent patients, with
functional biliary decompression obtained in 92 patients in both groups. In stented
patients, there was a lower procedure-related mortality (3% vs 14%, p=0.01), major
complication rate (11% vs 29%, p=0.02), and median total hospital stay (20 vs 26 days,
p=0.001). Recurrent jaundice occurred in 36 stented patients and 2 surgical patients.
Late gastric outlet obstruction occurred in 17% of stented patients and 7% of the
surgical group. Despite the early benefits of stenting there was no significant difference
in overall survival between the two groups (median survival: surgical 26 weeks; stented
21 weeks; p=0.065).
Endoscopic stenting and surgery are effective palliative treatments with the former
having fewer early treatment-related complications and the latter fewer late complica-
tions.
Lancet 1994; 344:1655-60
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PAPERDISCUSSION
Endoscopic treatment ofmalignant bile duct obstruction
has become an accepted alternative to surgical
bilioenteric by-pass during the last decade. There were,
however, only two prospective randomized comparisons
available1’2 until Smith and associates published their
study in 1994. They aimed at providing a basis for the
patients tomake fullyinformed decisions onwhether their
jaundice should be relieved endoscopically or surgically.
Unlike the previous two randomized studies1’2 Smith
and associateswere able to collect a sufficientnumber of
patients to make the results statistically reliable. Only
patients in whom the tumor was deemed unresectable
were included in the study and, thus, the question ofthe
role ofpreoperative biliary drainage was not addressed.
Aprerequisite fortheuse ofnon-surgical techniques for
palliative purposes is that available imaging tests cor-
rectly distinguish between resectable and unresectable
disease. We feel that Smith and associates, like several
other authors, overemphasize the power and accuracy of
such tests in this respect. We have to remember that data
are generally publishedfrom expert centers and that even
here the sensitivity obtained for different tests is farbelow
100% (3).
Therefore, patients who are otherwise fit will and
should undergo a laparotomy by an experienced sur-
geon irrespective ofwhether the imaging tests suspect a
locally unresectable lesion or not. The difficulties in
even verifying the diagnosis preoperatively are dem-
onstrated by Smith and associates who obtained histo-
logical or cytological proof in only two thirds of the
patients.
In our department percutaneous cytodiagnosis was
widely used during the 1970’s and the first half of the
1980’s, but due to the high proportion of false negative
findings it is today only practised in those with unques-
tionably advanced disease to strengthen the basis for the
discussion with the patient and his/her family on prog-
nosis and palliation (4). In patients with metastatic dis-
ease preoperative staging is often accurate especially if
cytology is done but the problematic clinical situation
arises in the patient with suspected local unresectability
who is otherwise healthy and fit for a major operation.
Then an exploratory laparotomy should always be done
preferably by a surgeon who is prepared to go on with a
pancreaticoduodenectomywhen appropriate.
The authors found an equal procedural and thera-
peutic success rate after endoscopic and surgical by-
pass, respectively. The procedure related mortality
was significantly lower after endoscopic than after sur-
gical bypass. However, the 30-day mortality was similar
in the two groups. Thus, the patients in the worst
general condition succumb early after surgery but after
endoscopic treatment they die anyhow within one
month, thus questioning the advantages ofendoscopy
in this particular respect. Furthermore, the postopera-
tive mortality rate was higher than reported in some
recent studies on palliative bilioenteric anastomoses 5’6’7.
One tentative reason for this could be that several ofthe
surgical bypasses were done in different referring hos-
pitals outside the Middlesex, whereas the endoscopy
was fully in the hands of the experts of this hospital.
There were fewer major early complications after
endoscopy than after surgery whereas late complica-
tions, such as recurrentjaundice and gastric outlet ob-
struction, were more frequent in the endoscopy group.
Surprisingly the rate of cholangitis attacks after the
two procedures, respectively, were not given. There
was no difference in overall survival between the two
treatments.
The study by Smith and associates is important as it
is prospective, randomized and of sufficient statistical
power. However, as pointed out above, the unexpect-
edly high early mortality rate after biliodigestive by-
pass does not do full justice to surgery, even if the
statistics are correct. Thefindings ofthe study, though,
lend support to the strategy which is currently practised
at many centers such as ours. All patients with a suspi-
cion ofextrahepatic biliary obstruction undergoERCP.
If a malignant typeof obstruction is found, stenting is
done at the same session. Patientswho turn out to suffer
from definitely incurable disease will get no further
treatment whereas those without signs ofmetastases or
clearcut unresectability on imaging tests will have a
laparotomy with the aim of resection. Staging laparo-
scopy is presently being evaluated but its clinical value
and cost-effectiveness needs confirmation (8).
Surgery has the advantage of offering at the same
time a definite evaluation of resectability, including
frozen section biopsy ofthe tumor and of secondaries,
resection or palliative procedures such as bilioenteric
shunt, gastroenteroanastomosis or coelic bloc, and
intraoperative radiotherapy (IORT) and/or clipping of
the tumor outline if a locally unresectable lesion is
planned for postoperative radiotherapy. Endoscopy
currently only offers routine relief of jaundice. How-
ever, recently biliary-type metallic stents have been
applied to relieve duodenal obstruction and the deve-
lopment of larger diameter devices has further im-
proved this early encouraging experience (9). Also,
there is some initial information on pain treatment by
placement of palstic stents in pancreatic cancer pa-
tients withmain duct obstruction. In carefully selectedHPB INTERNATIONAL 181
patients, the results are promising (10). For palliative
purposes the endoscopic approach in a broader sense
has also been applied laparoscopically as well as
thoracoscopically.
Cholecystojejunostomy and gastroenteroanastomosis
can be properly done via the laparoscopic route (11) and
pain relief can be achieved by thoracoscopic splanchni-
cectomy (12). Thus, both surgeryandendoscopycomprise
a greatarmamentariumand possibilities which today and
in the future may offer good and improved palliation to
patients with malignant disease affecting the common
bile duct and its surroundings.
Since thefirst endoscopic biliary drainageswere done,
the stent diameter has been successively increased in
order to counteract the problem of clogging causing
cholangitis and/or recurrent jaundice. Although Smith
and associates used 10 FG plastic stents, the risk of
recurrent biliary obstruction was significant. The
maximum diameter of plastic stents is limited by the
instrument channel and cannot be increased further
than the 10 to 11.5FGwhich isnow standard. The self-
expandable metallic stents may expand to 30FGwhen
in place in the bile duct. Randomized studies report
prolonged patency although tumor ingrowth has now
appeared as a cause ofstent occlusion3’14’5. This prob-
lem will hopefully be overcome by silicone coveting or
withmetallic stentswhichdonothaveanopenframework.
There is fast development in both the surgical, espe-
cially the laparoscopic, and the endoscopic approachs
to the palliative relief of malignant bile duct obstruc-
tion. The two techniques complement each other and
the study by Smith and associates helps in defining
their current roles.
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